Guidant gets OK to expand US DES (drug-eluting stent) trial:
This article was originally published in Clinica
The FDA has given Guidant the green-light to expand enrolment in the US portion of its SPIRIT III drug-eluting stent (DES) trial to the full cohort of 1,292 patients at up to 80 sites. The study is comparing the firm's everolimus-eluting stent, XIENCE V, with the current market-leading DES, Boston Scientific's paclitaxel-eluting stent, Taxus. Results from SPIRIT III will be used to seek FDA approval for XIENCE V for treating coronary artery disease. Guidant initially received conditional investigational device exemption approval to begin the trial with a limited number of sites in May. Some 117 patients have been enrolled in the study to date. XIENCE V comprises as its stent platform Guidant's cobalt chromium Multi-Link Vision system.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.